Advertisement
Utilizing the virus strain for the Northern Hemisphere recommended by theWorld Health Organization, Sinovac has commenced the production of Anflu(R)for the annual flu season based on its 2008-2009 production plan. The Chineseauthorities have recently completed the review of the batch release processand approved the vaccine for launch. In August 2008, the China CDC issued the2008 "Guidelines for Influenza Prevention and Control Technology" thathighlighted the positive public health implications of receiving the seasonalflu vaccine, the target population and the extension of the vaccinationduration. As an amendment to the 2007 version, the 2008 guidance expanded therecommended vaccination population to include people living in senior homes,nursing homes and chronic disease nursing facilities, along with childcareproviders who are looking after infants less than six month in age.
Advertisement
Over the past year, Sinovac has expanded its manufacturing capacity withthe construction of a pandemic influenza vaccine production line with annualcapacity of 20 million doses using the grant from China's National Developmentand Reform Commission. The production line includes state-of-the-artautomated production equipment along with an expanded packaging capability andaffords Sinovac the ability to produce up to five million doses of Anflu(R).By leveraging the latest production technology, the quality of the Anfluvaccine will be enhanced.
In line with its efforts incorporate the latest technology, Sinovac hasintroduced new insulation packaging to facilitate vaccine distribution. Basedon customer feedback, the packaging features color-coded insulated packagingthat effectively utilizes ice to maintain the desired temperature. Theupdated packaging enables the shipping of 50 or 100 doses.
Mr. Weidong Yin, Chairman, President and CEO, commented, "We are verypleased to launch Anflu(R) in China for the 2008 - 2009 seasonal influenzaseason. By utilizing our state-of-the-art production capability, we are wellpositioned to deliver our adult dosage formulation to our target market inChina."
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac'scommercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combinedhepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac iscurrently developing Universal Pandemic Influenza vaccine and Japaneseencephalitis vaccine. Additional information about Sinovac is available onits website, http://www.sinovac.com . To be added to our distribution list,please email: [email protected].
Safe Harbor Statement
This announcement contains forward-looking statements. These statementsare made under the "safe harbor" provisions of the U.S. Private SecuritiesLitigation Reform Act of 1995. These forward-looking statements can beidentified by words or phrases such as "will," "expects," "anticipates,""future," "intends," "plans," "believes," "estimates" and similar statements.Among other things, the business outlook and quotations from management inthis press release contain forward-looking statements. Statements that arenot historical facts, including statements about Sinovac's beliefs andexpectations, are forward-looking statements. Forward-looking statementsinvolve i
